HCPCS Level II code Q5154 describes an injection of omalizumab-igec (Omlyclo), a biosimilar formulation of omalizumab provided in 5 mg units; the service represents a biologic drug administration typically delivered as a subcutaneous injection in outpatient clinics, specialty infusion centers, or physician offices and is billed as a drug supply line item using the HCPCS Level II drug code.

For related coverage guidance, see recent payer policy updates: B-Hemolytic Streptococcus Testing, Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance Assays, Hepatitis Testing (A, B, C, D) Coverage Criteria.